Competition getting stiff for DPP-4 inhibitors

Published: 2011-09-30 06:57:00

Updated: 2011-09-30 06:57:00

Following Bristol-Myers Squibb’s Onglyza (saxagliptin), Boehringer Ingelheim finally won the approval of the Korea Food and Drug Administration for their diabetes drug Trajenta (linagliptin), a dipeptidyl peptidase 4 (DPP-4) inhibitor that will directly compete with Merck's fast-growing treatment...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK